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Background:Hypothalamic–pituitary–adrenal (HPA) axis functioning has been
implicated in the development of stress-related psychiatric diagnoses and response
to adverse life experiences. This study aimed to investigate the association between
genetic and epigenetics in HPA axis and response to cognitive behavior therapy
(CBT). Methods: Children with anxiety disorders were recruited into the Genes
for Treatment project (GxT, N = 1,152). Polymorphisms of FKBP5 and GR
were analyzed for association with response to CBT. Percentage DNA methyla-
tion at the FKBP5 and GR promoter regions was measured before and after CBT
in a subset (n = 98). Linear mixed effect models were used to investigate the re-
lationship between genotype, DNA methylation, and change in primary anxiety
disorder severity (treatment response). Results: Treatment response was not as-
sociated with FKBP5 and GR polymorphisms, or pretreatment percentage DNA
methylation. However, change in FKBP5 DNA methylation was nominally sig-
nificantly associated with treatment response. Participants who demonstrated the
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greatest reduction in severity decreased in percentage DNA methylation during
treatment, whereas those with little/no reduction in severity increased in per-
centage DNA methylation. This effect was driven by those with one or more
FKBP5 risk alleles, with no association seen in those with no FKBP5 risk alle-
les. No significant association was found between GR methylation and response.
Conclusions: Allele-specific change in FKBP5 methylation was associated with
treatment response. This is the largest study to date investigating the role of HPA
axis related genes in response to a psychological therapy. Furthermore, this is the
first study to demonstrate that DNA methylation changes may be associated with
response to psychological therapies in a genotype-dependent manner. Depression
and Anxiety 00:1–10, 2015. C© 2015 The Authors. Depression and Anxiety published by
Wiley Periodicals, Inc.
Keywords: anxiety; child/adolescent; cognitive behavior therapy; genetics; treat-
ment; biologicalmarkers; therapygenetics; DNAmethylation;HPA axis; FKBP5;
glucocorticoid receptor
INTRODUCTION
Hypothalamic–pituitary–adrenal (HPA) axis
functioning is known to play an important role in
reactivity to stress, and impairments in this system have
been widely implicated in psychiatric disorders such as
anxiety.[1–3] Stress exposure rapidly stimulates glucocor-
ticoid secretion, activating the “ﬁght or ﬂight” response.
Termination of this response involves binding of
glucocorticoids (i.e., cortisol) at the glucocorticoid
receptor. FK506-binding protein 51(FKBP5) acts as a
functional negative regulator of glucocorticoid receptor
sensitivity by reducing binding afﬁnity[4] and restricting
nuclear translocation.[5] FKBP5 mRNA expression
has been shown to be regulated by glucocorticoids via
glucocorticoid response elements, creating an ultrashort
negative feedback loop. Impaired negative feedback in
this process can lead to prolonged or excessive stress
responses, as seen in anxiety disorders.[1]
Genetic variation of FKBP5 has been found to in-
teract with early trauma or childhood adversity to pre-
dict negative outcomes later in life, such as susceptibil-
ity to posttraumatic stress disorder (PTSD), depression,
and suicidality.[6–10] Recent molecular research has sug-
gested that genotype-dependent structural differences in
FKBP5 may give rise to differential epigenetic changes
following early-life stress[11] and subsequently functional
alterations in the responsiveness of FKBP5 to glucocor-
ticoid receptor activation.[11] Epigenetic modiﬁcations
of the glucocorticoid receptor gene (NR3C1, referred
to here as GR) have also been associated with early-life
experiences in both rats and humans. Studies of early ex-
periences in rats found that DNA methylation of the GR
promoter region was altered by maternal care, which
in turn was associated with GR expression and HPA
responses to stress.[12] In humans, stressful life events
(e.g., trauma and abuse) have been associatedwith higher
DNA methylation at the GR promoter region[13–18] as
well as differential GR expression and biological mark-
ers of HPA-axis activity, such as salivary cortisol.[13,14]
Furthermore,GRmethylation has been implicated in the
development of PTSD following trauma.[19] Together,
these ﬁndings suggest that FKBP5 and GR genetic and
epigenetic differences may inﬂuence responsiveness to
stressful environments, and the development of stress-
related psychiatric disorders.
There is also increasing evidence that some genetic
factors thought to reﬂect vulnerability to stressful envi-
ronments may also be associated with more positive out-
comes in low-stress or enriching environments.[20] Few
tests of this differential susceptibility hypothesis have fo-
cused on genes involved in stress reactivity, though re-
cent research suggests that the risk allele of FKBP5 SNP
rs1360780 may be associated with increased risk of de-
pressive symptoms in victimized girls, and also lower
depressive symptoms in those with low levels of peer
victimization.[21] Given the role of HPA-axis genes such
as FKBP5 and GR in the biological response to envi-
ronmental stimuli, they are plausible candidates for in-
vestigation of response not only limited to adverse life
experiences such as trauma and abuse, but also to positive
experiences such as psychological therapies.
Anxiety disorders are associated with high levels of
stress. They can be highly debilitating, have the poorest
prognosis when they begin early, and show high conti-
nuity into adulthood.[22,23] Psychological therapies such
as cognitive behavior therapy (CBT) represent an ef-
fective treatment option for many children with anxiety
disorders, with 60% of children remitting following
CBT.[24] The ﬁeld of “therapygenetics” is a growing area
of research focusing on genetic predictors of outcome
in response to psychological therapies.[25] A small num-
ber of candidate genes have been implicated, focusing
primarily on polymorphisms and epigenetic regulation
of genes involved in brain-related markers, such as the
serotonin transporter gene (SERT[26–28]), brain-derived
neurotrophic factor (BDNF[29]), and nerve growth
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factor (NGF[30]), among others.[31] One study has exam-
ined FKBP5 genotype with respect to therapy outcome,
ﬁnding an association between the SNP rs1360780 and
the effectiveness of narrative exposure therapy for PTSD
(N = 43[32]). With respect to DNA methylation, a study
of PTSD in veterans indicated that DNA methylation
of FKBP5 and GR may be associated with response to
exposure-based psychotherapy in PTSD (N = 16[33]).
Pretreatment GR methylation predicted treatment re-
sponse, whereas a decrease in FKBP5 methylation across
treatment was associated with recovery. To date, no
studies have combined genetic and epigenetic data when
looking at the association between HPA axis related
genes and response to CBT.
In this study, we tested the association between poly-
morphisms of FKBP5 and GR and response to CBT in
children with anxiety disorders (N = 1,152), and exam-
ined change in DNA methylation at speciﬁc regions of
these genes during the course of CBT in a subset of
the sample (n = 98). Our ﬁrst hypothesis was that there
would be a signiﬁcant effect of stress reactivity related
genotypes on change in anxiety severity. Our second
hypothesis was that there would be an association be-
tweenFKBP5 andGRmethylation and response toCBT,
looking at prediction by pretreatment DNA methyla-
tion, and change in DNA methylation during treatment.
Previous research has demonstrated that DNA methy-
lation patterns are linked to DNA sequence variation
at a large number of locations across the genome,[34,35]
and allele-speciﬁc DNA methylation has also been re-
ported at in FKBP5.[11] Therefore, our third hypothesis
was that there would be an interaction between FKBP5
and GR genotypes and DNA methylation on CBT re-
sponse. This is the largest study to date that has inves-
tigated the association of FKBP5 and GR with response
to a psychological therapy, and the ﬁrst study of DNA
methylation and response to a psychological therapy to
include genotypic information.
PARTICIPANTS
STUDY OVERVIEW
All participants come from the Genes for Treatment
(GxT) Study, an international multisite collaboration
designed to identify predictors of outcome following
CBT for child anxiety.[28,36]
PARTICIPANTS AND TREATMENT
Subjects aged 5–18 (mean: 9.8 years) met DSM-IV
criteria for primary diagnosis of an anxiety disorder. Ex-
clusion criteria included signiﬁcant physical/intellectual
impairment, psychoses, and concurrent treatment. All
participants (N = 1,152) completed a full course of CBT
either as part of a trial or treatment as usual at one of
11 sites. Detailed sample characteristics and site-speciﬁc
trial details can be found in the Supporting Information
and in Table 1. T
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CLINICAL MEASURES
Anxiety disorders were assessed before and after treat-
ment, and at follow-up (3, 6, or 12 months after con-
clusion of treatment). Diagnoses were made with the
Anxiety Disorders Interview Schedule for DSM-IV
(ADIS-IV-C/P; [37]) at all sites except for Bochum and
Basel, where the German equivalent (Kinder-DIPs) was
used.[38] Clinical severity ratings (CSRs) were usually
based on composite parent and child reports, and were
assigned on a scale of 0–8.[36] Treatment response was
deﬁned as the change inprimary anxiety disorder severity
from pretreatment to follow-up. A diagnosis was made
when the child met diagnostic criteria and received a
CSR of 4 or more. Remission was regarded as the ab-
sence of the primary anxiety according to diagnostic cri-
teria, as determined by the clinicians at the follow-up
interview. Details of primary diagnoses included can be
found in the Supporting Information.
METHODS
GENOTYPING
Participants provided DNA using buccal swabs or Oragene saliva
samples (DNA Genotek, Ottawa, Canada). DNA was extracted us-
ing established procedures.[39,40] Genotypes for ﬁve FKBP5 poly-
morphisms (rs1360780, rs3800373, rs9296158, rs9470080, rs4713916)
and ﬁve GR polymorphisms (rs6189, rs6190/R23K, rs6195/N363S,
rs6198/GR-9beta, rs41423247/BcII1) were genotyped by LGC Ge-
nomics (Hoddesdon, UK) using validated arrays with KASP technol-
ogy or were obtained from the Illumina Core Exome array. SNPs were
included if they could be imputed with >90% completeness, and an in-
formation score of >.8. Four additional markers were genotyped using
both platforms to check for agreement across thesemethodologies, and
showed an average of 98% consensus on genotype calls. Using these
cutoffs, data were available for all FKBP5 SNPs, and two GR SNPs
(rs6195/N363S and rs4142324/BcII1).
DNA METHYLATION
A subset of participants had DNA samples available for two time
points—before and after treatment. All samples included in DNA
methylation analyses were derived from buccal swabs. These partici-
pants were treated at Sydney, Australia (n = 74) and Reading or Ox-
ford, UK (n = 24). In these samples, extracted genomic DNA (510 ng)
was treated with sodium bisulﬁte using the EZ-96 DNA Methylation
Kit (Zymo Research, USA). Sequences were chosen based on their
proximity to the gene promotor region and CpG islands—further ra-
tionale details are provided in the Supporting Information. Bisulﬁte-
PCR primers for the FKBP5 and GR amplicons were designed using
the Sequenom EpiDesigner software (Supporting Information Table
S1). PCR ampliﬁcation was conducted using 40 cycles at an annealing
temperature of 63/56°C (FKBP5/GR), with Qiagen HotStarTaq DNA
Polymerase andSequenomMassCLEAVE taggedprimers. Percentage
DNA methylation was quantitatively measured using the Sequenom
EpiTYPER system (Sequenom, SanDiego,CA,USA). Artiﬁcially fully
methylated and unmethylated samples were included for quality con-
trol, and any probes detecting an average DNA methylation of <5%
were dropped from further analyses. Following stringent quality con-
trol, quantitative methylation data were available for four FKBP5 CpG
probes and four GR CpG probes (n = 98), referred to as CpG 1–4 in
the results.
ETHICS APPROVAL
Research was conducted in compliance with the standards outlined
by the Declaration of Helsinki. All trials and collection of samples
were approved by site-speciﬁc Human Ethics and Biosafety Commit-
tees. Parents provided informed consent, children assent. The storage
and analysis of DNA was approved by the King’s College London
Psychiatry, Nursing and Midwifery Research Ethics Sub-Committee.
ANALYSES
TREATMENT OUTCOME
Tomaximize power,we focusedour analyses on change
in primary anxiety disorder severity from pretreatment to
follow-up. We refer to this from hereon as treatment re-
sponse. Signiﬁcant predictors were then considered with
respect to remission of the primary diagnosis. Follow-up
assessments were usually conducted 6 months after the
conclusion of treatment (participants with 3- and 12-
month follow-ups were also included; see Supporting
Information).
ETHNICITY
Self-reported ethnicity was available for 73.9% of the
sample, of whom 87.0% were of white-European ances-
try. Ethnicitywas unrelated to genotypic proportions (all
SNPs P >.05, see Supporting Information Table S2) or
treatment outcome (β = .01, P =.276).
Genotype. High-quality genotype and follow-up
outcome data were available for 924 children for FKBP5
markers, and 1,000 children for GR.
Linear mixed effect models were used to test the ef-
fect of FKBP5 and GR polymorphisms on treatment
response. Treatment trial was included as a higher
order random effect in order to account for differ-
ences between trials (see Supporting Information and
Table 1). Gender, age, and baseline severity were in-
cluded as covariates, with age and baseline severity cen-
tered at the mean. Analyses also included the linear
and quadratic effects of time as covariates. As all SNPs
showed a low frequency of the homozygous risk allele
genotype, polymorphisms were coded to reﬂect a dom-
inant model, with homozygotes of the “non-risk” allele
versus “risk” allele carriers. This is in accordance with
previous studies of response to environmental stimuli
and psychiatric outcomes [32,41] and interactions between
genotype and DNA methylation.[11]
DNA Methylation. Prediction of treatment re-
sponse was assessed using pretreatment percentage
DNA methylation values. Change in DNA methylation
from pre- to posttreatment was also calculated for all
CpG sites. Linear mixed effect analyses were used to test
the association between percentage DNA methylation
(both pretreatment and change) and change in clinical
severity from pretreatment to follow-up. Age (centered),
gender, and baseline severity (centered) were included as
covariates in all models, and treatment trial was included
as a higher order random effect.
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Genotype and DNA Methylation Interaction
Analyses. To test the effect of genotype on the as-
sociation between percentage DNA methylation and
treatment outcome, linear mixed effect models were run
as previously described, including an interaction term
(genotype×DNAmethylation). As before, prediction of
treatment response was assessed using pretreatment per-
centage DNA methylation. Change in percentage DNA
methylation from pre- to posttreatment was also tested
for association with treatment response.
FKBP5. A high correlation was observed between all
FKBP5 SNPs (r = .72–.99), and all SNPs ﬁt the same
pattern of genotypic distribution as rs1360780. Previ-
ous research has indicated that rs1360780 may play a
functional role in the interaction between environmental
stimuli and DNA methylation,[11] with genotype coded
using a dominant model. Therefore, FKBP5 genotype
was collapsed to reﬂect those with no “risk” alleles, ver-
sus those with one or more risk allele (0 = 41.3%, 1–5
= 58.7%1 ).
GR. Only one GR SNP (rs4142324) showed sufﬁ-
cient variability in the available sample to be included
in the interaction analyses. As before, a dominant model
(GC/CC vs. GG) was used for GR genotype.
All analyses were performed in STATA version
11.2 .[42]
Multiple Testing. To correct for multiple testing,
revised signiﬁcance thresholds were estimated. These
values were calculated using Matrix Spectral Decom-
position (MatSpD)[45] to determine the number of in-
dependent variables in the data. First, for the genotypic
analysesMatSpD indicated that the seven SNPs tested in
the genotypic analyses corresponded with 4.8 indepen-
dent variables (α <.0104). Second, for analyses of DNA
methylation the eight CpG sites examined corresponded
with 7.8 independent variables (α <.0064). Third, to ac-
count for the additional effect of genotype included in
the interaction analyses (two possibilities; risk vs. no-
risk), this value was divided by two, giving a threshold of
α <.0032.
RESULTS
Clinical outcomes were comparable to previously re-
ported estimates. Following treatment, 54.4/38.3% of
the sample was free of their primary/all anxiety diag-
noses, respectively. By follow-up, these rates rose to
65.6% for the primary diagnosis, and 49.0% for all anx-
iety diagnoses. Mean severity at pretreatment was 6.3
(sd = 1.0), dropping to 3.2 (sd = 2.2) at posttreatment,
and 2.5 (sd = 2.2) at follow-up.
GENOTYPE AND THERAPY OUTCOMES
There was no signiﬁcant effect of FKBP5 or GR geno-
type on treatment response (Table 2).
1Note: Only 11.7% of the sample had one to four risk alleles, therefore
the majority of those in the “1+ risk alleles” group had ﬁve risk alleles.
DNA METHYLATION AND RESPONSE TO
THERAPY
Preliminary Analyses. Therewas no time-point ef-
fect on DNA methylation (n = 98), with no signiﬁ-
cant differences between pre- and posttreatment DNA
methylation detected for any CpG site in either FKBP5
or GR (Supporting Information Table S3).
Prediction. Analyses of pretreatment FKBP5 and
GR methylation showed no association with treatment
response at anyCpG site (Supporting InformationTable
S4).
Change. FKBP5.Therewas a signiﬁcant association
between change inCpG4methylation frompre- to post-
treatment, and treatment response (β = .04, P = .0069,
Figure 1). Speciﬁcally, increased DNA methylation was
associated with a smaller reduction in symptom severity,
whereas a decrease in DNA methylation was associated
with a greater reduction in symptom severity. However,
this effect did not remain signiﬁcant when corrected for
multiple testing (α < .0064). There was no signiﬁcant
association between change in percentage DNA methy-
lation at CpG sites one to three and treatment outcomes
(Figure 1).
GR.Change inDNAmethylationwas not signiﬁcantly
associated with treatment outcome for any GR CpG site
(Figure 1).
INTERACTION BETWEEN GENOTYPE AND DNA
METHYLATION ON TREATMENT OUTCOMES
Preliminary Analyses. Therewas no effect of geno-
type on pretreatment percentage DNA methylation or
change in percentage DNA methylation at any CpG site
for FKBP5 or GR (Supporting Information Table S5).
Prediction. There was no signiﬁcant effect of an in-
teraction between genotype and pretreatment percent-
age DNA methylation on treatment response for either
FKBP5 or GR (Supporting Information Table S6).
Change. FKBP5. At CpG 4, there was a nomi-
nally signiﬁcant interaction between change in percent-
age DNA methylation, FKBP5 genotype, and treat-
ment response (β = .14, 95% CI =.02–.27, P = .028,
Figure 2), although thiswas not signiﬁcantwhen correct-
ing for multiple testing. Interestingly, in those with the
risk allele genotype, change in CpG 4 percentage DNA
methylation was associated with treatment response
(β = .06, 95% CI =.03–.10, P = 1.3 × 10−4), but
not in those with no risk alleles (β = .002, 95% CI
=−.04 to .05, P = .905). The same pattern of effects was
observed in post hoc analyses of primary anxiety diag-
nosis remission (See Supporting Information). The as-
sociation between change in percentage DNA methyla-
tion and treatment response in participants with the risk
genotype remained signiﬁcant when corrected for mul-
tiple testing. There was also a nominally signiﬁcant in-
teraction between change in DNA methylation at CpG
1, FKBP5 genotype, and treatment response (β = .20,
95% CI =.05–.35, P = .008). At this CpG site, those
with the risk allele showed the same pattern of DNA
Depression and Anxiety
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TABLE 2. Genotype and primary anxiety response
Gene Polymorphism
Mean primary anxiety
response (SE) β 95% CI P
FKBP5 rs1360780 CC = −3.79 (.11)
CT/TT = −3.7 (.10)
.01 −.05 to .06 .847
Age .00 −.01 to .01 .965
Sex .04 −.01 to .09 .150
Baseline severity .25 .23 to .28 <.001
Time −1.13 −1.17 to 1.08 <.001
Time2 .18 .17 to .19 <.001
rs3800373 TT = −3.74 (.11)
TG/GG = −3.76 (.10)
−.01 −.06 to .04 .668
Age .00 −.01 to .02 .739
Sex .05 −.00 to .10 .072
Baseline severity .25 .22 to .28 <.001
Time −1.13 −1.17 to 1.08 <.001
Time2 .18 .17 to .19 <.001
rs4713916 GG = −3.78 (.11)
GA/AA = −3.68 (.11)
.00 −.05 to .06 .931
Age .00 −.01 to .02 .557
Sex .04 −.01 to .10 .148
Baseline severity .25 .22 to .28 <.001
Time −1.13 −1.18 to 1.08 <.001
Time2 .19 .17 to .20 <.001
rs9296158 GG = −3.78 (.11)
GA/AA = −3.70 (.10)
.01 −.05 to .06 .791
Age .00 −.01 to .02 .705
Sex .05 −.00 to .10 .071
Baseline severity .25 .22 to .28 <.001
Time −1.13 −1.17 to 1.08 <.001
Time2 .18 .17 to .19 <.001
rs9470080 CC = −3.76 (.12)
CT/TT = −3.74 (.09)
.00 −.06 to .05 .933
Age .00 −.01 to .02 .768
Sex .05 −.00 to .10 .064
Baseline severity .25 .22 to .28 <.001
Time −1.13 −1.17 to 1.08 <.001
Time2 .18 .17 to .19 <.001
GR rs6195 AA = −3.76 (.07) AG =
−3.58 (.27)
−.04 −.15 to .08 .542
Age .00 −.01 to .02 .719
Sex .05 .00 to .11 .046
Baseline severity .25 .22 to .28 <.001
Time −1.12 −1.17 to 1.08 <.001
Time2 .18 .17-.19 <.001
rs41423247 GG= −3.82 (.09)
GC/CC = −3.72 (.12)
.00 −.05 to .06 .959
Age .00 −.01 to .01 .850
Sex .04 −.01 to .10 .111
Baseline severity .24 .22 to .27 <.001
Time −1.13 −1.18 to 1.09 <.001
Time2 .18 .17 to .19 <.001
Primary anxiety response is deﬁned as the change in severity for the primary diagnosis from pretreatment through follow-up time points.
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Figure 1. Association between change in FKBP5 and GR methy-
lation and primary anxiety response.
Note: The values given for the beta (β) coefficient are absolute,
and refer to the main effect of change in percentage DNAmethy-
lation on primary anxiety response (change in primary anxiety
disorder severity from pretreatment to follow-up). ∗P = .0069,
nominally significant.
methylation change as for CpG 4, while those with
no risk alleles showed the opposite pattern of effect
(Figure 3). There was no effect of an interaction between
genotype and change in percentage DNA methylation
for CpG sites 2 and 3.
GR. There was no signiﬁcant effect of an interaction
between change in percentage DNA methylation and
GR genotype on treatment response for any CpG site
(Supporting Information Table S7).
DISCUSSION
This study utilizes a large sample to test the association
betweenHPA-axis related genes and response to psycho-
logical therapy, including both genetic and epigenetic
information as predictors of treatment outcome. We
found suggestive evidence for an association between
change in FKBP5 methylation and treatment response.
This is comparable to previous reports of FKBP5methy-
lation change and psychological therapy response.[33] Of
note, in our sample this effect was largely driven by those
with the “risk” genotype, suggesting that this association
may be genotype dependent. Intriguingly, allele-speciﬁc
methylation of FKBP5 intron 7 was previously demon-
strated to be associated with childhood trauma,[11] which
suggests that this may be one mechanism by which nega-
tive experiences early in life affect long-term susceptibil-
ity to stress-related disorders, such as anxiety and CBT.
The current study focuses on a different region of the
FKBP5 gene, but our ﬁndings indicate that genotype-
dependent change in FKBP5 methylation may also be
associatedwith positive environmental inﬂuences; in this
case, psychological therapy. Furthermore, it is possible
Figure 2. Association between change in FKBP5methylation and
primary anxiety response as a function of FKBP5 genotype.
Note: Treatment response is depicted as reduction in primary
anxiety disorder severity, which takes into account the baseline
(pretreatment) severity, thus reflectingmore accurately themod-
els tested (which included pretreatment severity as a covariate).
Note that a larger reduction in symptom severity represents a
greater response to treatment. No risk alleles: β = .002, 95%
CI = −.04–.05, P = .905 n = 34; 1+ risk alleles: β = .06, 95% CI
= .03–.10, P = 1.3 × 10−4, n = 52. Interaction: β = .14, 95% CI
= .02–.27, P = .028.
that the effects described reﬂect a molecular mecha-
nism by which some people are more or less reactive
to their environment. In our sample, individuals with
the FKBP5 “risk” genotype showed greater variability
in DNA methylation changes and treatment outcome.
A greater response to therapy (i.e., greater reduction in
severity) was associated with decreases in FKBP5 methy-
lation, whereas a poorer response to therapy was as-
sociated with increases in FKBP5 methylation. This is
consistent with a differential susceptibility framework,
whereby individuals with particular genetic factors may
be more vulnerable to their environment, “for better or
for worse.”[20] The same pattern of association was seen
in risk genotype individuals for a further CpG site in the
same region, while no-risk genotype individuals showed
an opposite pattern of effect. These ﬁndings highlight
the allele-speciﬁc nature of DNA methylation changes
at this region in our sample.
We did not ﬁnd any effect of FKBP5 or GR geno-
type, or pretreatment DNA methylation on treatment
response. Previous research suggested that the FBKP5
genotype rs1360780 is associated with response to narra-
tive exposure therapy in adults with PTSD (N = 43).[32]
We did not replicate this ﬁnding in the current large
sample of response to CBT in children with anxiety dis-
orders (rs1360780, n = 912). In a sample of this size
(>900), we were well powered to detect even small-
medium effect sizes (e.g., >80% power to detect an ef-
fect size of d = .26 at a signiﬁcance level of α = .05).
Moreover, we did not observe a signiﬁcant association
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Figure 3. Interaction between change in FKBP5methylation and
FKBP5 genotype on primary anxiety response.
Note: Treatment response is depicted as reduction in primary
anxiety disorder severity, which takes into account the baseline
(pretreatment) severity, thus reflectingmore accurately themod-
els tested (which included pretreatment severity as a covariate).
Note that a larger reduction in symptom severity represents a
greater response to treatment. Interaction β = .20, 95% CI =
.05–.35, P = .008.
between pretreatment or change in GR methylation and
treatment outcome. This is in contrast to the previously
reported ﬁnding that pretreatment GR methylation pre-
dicted treatment response in veterans with PTSD.[33]
Higher GR methylation has been associated with early-
life adversity, such as childhood abuse or maltreatment,
or prenatal exposure tomaternal anxiety, depression, and
stress[13–16,18] In these studies, higher methylation was
associated with reduced GR expression[13] and also in-
creased salivary cortisol responses to stress.[14] The ab-
sence of an association in our sample may suggest that
GR methylation levels are more susceptible to traumatic
experiences, and may be more stable over time. How-
ever, it should also be noted that our DNA methylation
analyses relied on a smaller subsample, and would ideally
be replicated in a larger dataset.
To date, only a handful of studies have examined
DNA methylation patterns with response to psycho-
logical therapy. A previous study of PTSD in veter-
ans found that pretreatment GR methylation patterns
predicted treatment outcome while FKBP5 methyla-
tion decreased across the course of therapy in treat-
ment responders, but increased in nonresponders.[33]
Another study examining response to intensive dialecti-
cal behavior therapy in adults with borderline personal-
ity disorder demonstrated differential patterns of BDNF
methylation change associatedwith scores of depression,
hopelessness, and impulsivity following treatment.[29]
Finally, we previously showed that one CpG site up-
stream of the SERT promoter increased in DNA methy-
lation during the course of therapy in treatment respon-
ders, but decreased in nonresponders.[27] Intriguingly,
in all of these studies responders and nonresponders
showed a difference in the direction ofDNAmethylation
change.
This study is the largest to date to examine genetic
markers involved in stress reactivity for association with
response to CBT. Furthermore, this is the ﬁrst study to
demonstrate that genotype-dependent changes in DNA
methylation are associated with response to psychologi-
cal therapy. However, there are some limitations. First,
analyses using the whole dataset contain participants
with a range of anxiety diagnoses, treated with different
CBTmodalities, leading to a high level of heterogeneity.
Second, while we were able to assess DNA methylation
at both pre- and posttreatment, we have no DNA sam-
ples to measure percentage DNA methylation for these
markers at follow-up. In this study, we ﬁnd genotype-
dependent changes in methylation during treatment
are associated with treatment outcomes at follow-up.
Previous studies investigating both genetic[26,30,32] and
epigenetic[26,27] markers of response to psychological
therapy have also demonstrated the largest effects at
follow-up. Future research of predictors and markers
of response to psychological therapies would be im-
proved by including this time point. Third, studies in-
vestigating biological and molecular changes in living
patients require the use of peripheral tissue as a proxy
for more speciﬁc tissues of interest. Furthermore, the
use of a child sample in this study necessitated the use of
minimally invasive DNA sampling techniques, namely
buccal swabs and saliva. However, while tissue-
speciﬁc differences in DNA methylation have been
documented,[43] it has been suggested that buccal swabs
may be more representative than other peripheral tis-
sues such as blood in epigenetic studies.[44] This is due
to a reduced cell heterogeneity in buccal swabs, and
because they originate from the same developmental
pathways as brain tissue.[44] Fourth, information on ex-
posure to trauma prior to treatment was not available
for this sample. Traumatic experiences in childhood
have been demonstrated to have lasting effects on DNA
methylation of both the FKBP5 andGR genes.[11,12,14–17]
Therefore, we are unable to make any conclusions re-
garding other environmental factors that may have in-
ﬂuenced baseline DNA methylation and subsequent
changes in DNA methylation during active treatment.
Finally, we could not make any inferences about the po-
tential functionality of the genotype-dependent methy-
lation changes observed as we were unable to measure
FKBP5 or GR expression in this cohort. Previous stud-
ies have demonstrated that FKBP5 expression is associ-
atedwithDNAmethylation, although it should be noted
that this study focused on methylation of FKBP5 intron
7.[11] Furthermore, a previous study of FKBP5 and GR
and response to psychological therapy found that en-
docrine markers of HPA-axis activity were predictive of
FKBP5 and GR gene expression at follow-up, and that
plasma cortisol was correlated with expression of both
genes.[33] Future studies would beneﬁt from utilizing
an integrative approach, by combining genotype, DNA
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methylation, and mRNA expression data when examin-
ing these markers.
CONCLUSION
In this study, we provide preliminary evidence that
response to a psychological therapy may be associated
with genotype-dependent changes in DNA methylation
of FKBP5, which is related to HPA-axis functioning and
responsiveness to stress. These results require replica-
tion, but add to the growing literature demonstrating
that response to environmental inﬂuences (both positive
and negative) is associated with changes at a biological
level.
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